Trademark Infringement versus Public Health: The Conflict Between Anti-Counterfeiting Laws And Access To The Generic Medicines

Abstract

The interface Between intellectual property right and public health has emerged as one of the most contested terrains of contemporary IPR Jurisprudence. We often think of trademark law as something that protects consumers from confusion. And in medicines, that protection becomes even more critical because a mistake can cost a life. But the same law, when it is stretched beyond its purpose through border enforcement and anti-counterfeiting rules, can actually block access to life-saving drugs. This paper started from a very simple question - what happens when a generic medicine, which is legal, licensed and has its own distinct brand name, is stopped at a port because it looks similar to a big pharma brand? In 2008-09, Dutch customs did exactly that. They seized 19 consignments of Indian generics which were not even meant for Europe, they were going to Brazil, Nigeria and Peru under the UNITAID programme. India today is called the Pharmacy of the World for a reason. We supply about 20% of global generic exports and almost 62% of anti-retroviral drugs used in Africa. So when you stop an Indian generic, you are not just stopping a trademark issue, you are stopping a patient's treatment. Through this research, I have tried to show that the real problem is conflation - we are mixing three different things under one word "counterfeit". Spurious drugs under the Drugs and Cosmetics Act is a quality issue, counterfeit trademark goods under the Trade Marks Act is an IPR issue, and generic drugs are a completely legitimate category. WHO itself understood this confusion and in 2017 dropped the term counterfeit and adopted Substandard and Falsified. India still has not. This paper analyses TRIPS Footnote 14, the EU Regulations, ACTA, WTO dispute DS408, Indian case law like Cadila and Novartis, and comparative law from USA, EU, Brazil and South Africa, to argue that our current customs rules are TRIPS-plus and violate Articles 7, 8, 41 of TRIPS and GATT Article V. I have proposed a concrete model clause - a public health defence under Section 30 of the Trade Marks Act.